GE Medical Systems has signed a clinical trial agreement with the National Cancer Institute’s Cancer Imaging Program. The multisite clinical trials will evaluate 18F-fluorothymidine (FLT) as an agent for PET studies.
Used to image DNA synthesis, FLT has shown preliminary promise for the in-vivo imaging of cellular proliferation. The NCI will sponsor clinical trials at Johns Hopkins Medical Institutions, Virginia Commonwealth University Medical Center, Massachusetts General Hospital, the University of Washington, and the National Institutes of Health Clinical Center, according to Waukesha, WI-based GE.
The vendor will provide the sites with its TRACERlab FX synthesis systems for production of FLT. GE said it anticipates that FLT will be one of the first PET agents for which there will be a FDA investigational new drug (IND) proceeding for the NCI-sponsored multi-site trials. The clinical trials are the first of an imaging agent being supported by GE.
By AuntMinnie.com staff writersNovember 24, 2003
Related Reading
GE expands capabilities of Infinia Hawkeye SPECT/CT, November 13, 2003
GE installs first Centricity 2.0 network, November 11, 2003
GE adds Centricity enterprise site, October 31, 2003
GE signs Catholic Health, October 21, 2003
GE signs Saint Francis, September 9, 2003
Copyright © 2003 AuntMinnie.com
![Examples of ultrasound findings and techniques. (A) Images in a 39-year-old male patient with a mass in the left thigh. The mass is heterogeneous on the B-mode US image (compared with the patient in D) and showed increased microvascularity (superb microvascular imaging [SMI]) and shear-wave elastography (SWE) values. Undifferentiated pleomorphic sarcoma was diagnosed at biopsy (with pleomorphic rhabdomyosarcoma in surgical specimen). (B) Images in an 18-year-old male patient with a mass in the left leg. The mass is hypoechoic on the B-mode image, with no other findings suggestive of malignancy. The lesion is in contact with the cortex of the tibia, which is slightly irregular. CT revealed a doubtful anteromedial tibial erosion. The microvascular study demonstrated high vascularization, suggestive of malignancy. Periosteal Ewing sarcoma was diagnosed with both histologic and immunohistochemical confirmation. (C) Images in a 69-year-old female patient with a lump growing on the outside of the left leg. Multiple SWE examinations were performed (please note the high values obtained in the measurements, whereas the color map highlights the stiffness relative to adjacent tissues). SMI showed areas of increased vascularization to target for sampling. Undifferentiated spindle cell sarcoma was diagnosed at biopsy, with residual leiomyosarcoma in the surgical specimen after neoadjuvant therapy. (D) Images in a 56-year-old female patient with a mass in the right thigh. The mass is heterogeneous at both B-mode ultrasound (similar to patient A) and MRI (coronal T2-weighted spectral attenuated inversion recovery [SPAIR]; T1-weighted pre-contrast and postcontrast imaging), which even shows uptake after the administration of paramagnetic contrast material, which is traditionally suggestive of malignancy. Low values at SMI and elastography are suggestive of benignity. Spindle cell lipoma was diagnosed at biopsy, with atypical spindle cell lipomatous tumor in the surgical specimen.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/08/images-radiol250278fig2.APCFLSvX6p.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
